In the frustrating search for a drug that can halt osteoarthritis (OA), targeting inflammation has been the most logical frontier. A recent landmark trial, published by Zhu and colleagues in JAMA Internal Medicine, took this theory head-on, testing the potent anti-inflammatory methotrexate (MTX) with a crucial design strength: every participant had thei…
